566 reports of this reaction
2.0% of all DOLUTEGRAVIR SODIUM reports
#8 most reported adverse reaction
HEADACHE is the #8 most commonly reported adverse reaction for DOLUTEGRAVIR SODIUM, manufactured by ViiV Healthcare Company. There are 566 FDA adverse event reports linking DOLUTEGRAVIR SODIUM to HEADACHE. This represents approximately 2.0% of all 28,565 adverse event reports for this drug.
Patients taking DOLUTEGRAVIR SODIUM who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for DOLUTEGRAVIR SODIUM, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for DOLUTEGRAVIR SODIUM:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 566 FDA reports for DOLUTEGRAVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 2.0% of all adverse event reports for DOLUTEGRAVIR SODIUM, making it a notable side effect.
If you experience headache while taking DOLUTEGRAVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.